1. Scrip
  2. >>Business
  3. >>Strategy

Lilly Doubles Down on Insomnia with Hypnion Acquisition

 
• By Chris Morrison

Eli Lilly added its second insomnia program with the acquisition of privately held Hypnion Inc. Hypnion's Phase II HY10275 compound is the industry's most advanced dual H1/5HT2a antagonist in clinical development. Hypnion management told START-UP that M&A was its preferred exit, given the resources necessary to develop HY10275 to its full potential.

The market for private biotech acquisitions is anything but sleepy. In early March Eli Lilly & Co. joined the fray, snapping up Hypnion Inc., a private developer of treatments for insomnia and sleep disorders. [See Deal]

The companies have kept a lid on the exact price Lilly paid for Hypnion, but based on information in a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Stock Watch: Q2 Sales Growth Sparks Diverging Reactions To J&J And Novartis

 
• By Andy Smith

With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By Kevin Grogan

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: J&J delivers in Q2 despite Stelara drop; Sarepta cuts jobs as Elevidys slumps; AI is inevitable but needs to be applied appropriately; China’s mid-cap companies thrive; and a look behind Glenmark’s landmark trispecific deal.